Abstract:
Obstructive sleep apnea (OSA) is a common chronic disorder characterized by recurrent upper-airway collapse during sleep, with an estimated 936 million individuals aged 30–69 years affected worldwide. OSA not only causes excessive daytime sleepiness and sleep fragmentation but may also increase the risk of cardiovascular and metabolic diseases through mechanisms such as intermittent hypoxia. Positive airway pressure (PAP) remains a primary treatment for moderate-to-severe OSA; however, suboptimal long-term adherence limits its real-world benefits. Recent advances in OSA treatment include the following: tirzepatide significantly reduces the apnea-hypopnea index in patients with obesity and OSA; multitarget combination pharmacotherapy, represented by atomoxetine combined with antimuscarinic agents, offers a new direction for OSA drug treatment; hypoglossal nerve stimulation provides an alternative for eligible patients who cannot tolerate PAP or have experienced PAP treatment failure, with favorable long-term adherence and patient satisfaction; advances have also been made in the digital fabrication of oral appliances and their cardiovascular benefits, with mandibular advancement devices demonstrating blood pressure–lowering effects noninferior to those of continuous positive airway pressure (CPAP) in patients with moderate-to-severe OSA who have hypertension and increased cardiovascular risk; and surgical treatment has shifted from single-level resection to precise multilevel reconstruction guided by drug-induced sleep endoscopy. OSA management is moving from a disease-centered, standardized approach toward individualized, integrated care based on phenotyping. This article reviews recent advances and individualized strategies in OSA treatment to inform clinical practice.